RAMBUS INC (RMBS): what the price assumes
In the published model solve dated 2026-Q2, anchored at $97.29, RAMBUS INC (RMBS) is priced for today's economics sustained for ~15.6 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.
Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/RMBS
Headline
| Field | Value |
|---|---|
| Ticker | RMBS |
| Company | RAMBUS INC |
| Current price | $97.29/sh |
| Composition | Product revenue 49% / Royalties 39% / Contract and other revenue 11% |
What The Price Assumes (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | whole-company |
| Operating margin (value-band context) | 34.4% |
| Operating margin today | 35.9% |
| Margin compression (value-band) | -1.5pp |
| Must persist for | 15.6y |
| Multiple paid | 40x operating income |
The operating-margin figure is value-band context at year 9: derived from the framework's value band, a separate calculation — not part of the priced-in solve.
Solve inputs: computed at a 12.7% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.5 years.
Reconcile: at the x-ray's 9.3% required return this reads ~8.2 years; the models below use their own rates.
How unusual the bet is: elevated
| Reference | Value |
|---|---|
| vs own history | -0.12σ |
| cohort percentile (of 187 peers) | 68 |
| sustained it ~10 years at this level | 15% |
| implied end-window share | 0% |
Valuation X-Ray
Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 3.97x | 5 | expensive |
| Earnings | 3.43x | 5 | expensive |
| Relative | 2.26x | 5 | expensive |
| Growth | 0.98x | 3 | justifies |
Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.
Per-Model Detail (n=18)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $99.50 | 0.98x | yes | FCF base $0.4B, growth 20% (input: historical growth), terminal g 4.0%, WACC 9.2%, 6yr projection |
| DCF Exit Multiple | Growth | $114.78 | 0.85x | yes | Exit EV/EBITDA: 34.4x / 36.4x / 38.4x (bear / base = today's held flat / bull), 6yr |
| Relative Valuation | Relative | $66.49 | 1.46x | yes | P/E 29.32x (blended: static sector reference 22x + trailing (TTM) 46x), scenarios: 24.0x / 29.3x / 34.7x (bear / base = reference held flat / bull), EV/EBITDA 22.13x |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $22.66 | 4.29x | yes | BV/sh $12.70, ROE (TTM) 16.5%, ke 9.3% |
| Two-Stage Excess Return | Asset | $29.89 | 3.25x | yes | 5yr excess ROE then converge to ke=9.3% |
| Discounted Future Market Cap | Growth | $86.50 | 1.12x | yes | Rev $0.7B, growth 20% (input: historical growth; tapered), Terminal P/S: 9.8x / 12.0x / 14.2x (bear / base = today's held flat / bull, cap 12x) |
| Peter Lynch Fair Value | Relative | $30.64 | 3.18x | yes | EPS $2.10, growth 15% (input: historical EPS growth), PEG=3.18 (Overvalued) |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $13.92 | 6.99x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.16B × (1−13%) / WACC 9.2% → EPV (no growth) |
| Residual Income | Asset | $30.23 | 3.22x | yes | BV $12.70 + 5yr PV of (ROE (TTM) 16.5% − Kₑ 9.3%) × BV; BV grows 8.8%/yr |
| Graham Number | Asset | $24.50 | 3.97x | yes | √(22.5 × EPS $2.10 × BVPS $12.70) — Graham's conservative floor |
| EV/EBITDA Relative | Relative | $43.12 | 2.26x | yes | EBITDA $0.29B × sector EV/EBITDA 16.0x |
| FCF Yield | Earnings | $33.69 | 2.89x | yes | FCF $335.2M / Kₑ 9.3% — zero-growth perpetuity |
| SBC-Adj FCF Yield | Earnings | $28.34 | 3.43x | yes | SBC-adj FCF $0.28B (FCF $0.34B − SBC $0.05B) capitalized at Kₑ |
| Ben Graham Formula | Earnings | $66.31 | 1.47x | yes | EPS $2.10 × (8.5 + 2×14.6%) × (4.4 / 5.3%) |
| ROIC-Justified P/B | Asset | $5.63 | 17.28x | yes | BV $12.70 × (ROIC 4.1% / WACC 9.2%) |
| P/Sales Sector | Relative | $32.86 | 2.96x | yes | Revenue $0.72B × sector P/S 5.0x |
| PEG Fair Value | Relative | $45.95 | 2.12x | yes | EPS $2.10 × (PEG 1.5 × growth 14.6% (input: historical EPS growth)) → PE 21.9x |
| Earnings Yield | Earnings | $22.70 | 4.29x | yes | EPS $2.10 / required return 9.3% (Rf 4.3% + ERP 5.0%) |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Economic-Unit Decomposition (Sum Of The Parts)
Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.
| Unit | Role | Valuation basis | Revenue | Reported profit | Value evidence | Status |
|---|---|---|---|---|---|---|
| Rambus (consolidated) | operating | enterprise | 0.7B reported-currency | — | withheld | unresolved no unit value |
No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.
Solvency
| Field | Value |
|---|---|
| Net cash | $786.1m |
| Net debt / NOPAT (after-tax) | -3.48x (net cash) |
| Net debt / operating income (pre-tax) | -3.04x (net cash) |
| Interest coverage | 203.0x |
| Share count CAGR (dilution) | 0.0% |
| Burning cash | no |
Bullet Takeaways
- Rambus makes the chips that keep high-speed memory reliable, principally DDR5 register clock drivers that sit on server memory modules, and it pairs that product business with a steady royalty stream from its memory-interface patents, so revenue comes from both selling silicon and licensing the IP behind it.
- The price is the risk: at roughly 60 times operating income the stock implies growth held at its self-funding ceiling for around two decades, a pace only about 15 percent of fast-growers have sustained for even ten years, so the AI-memory tailwind is being extrapolated far into the future.
- Watch product-revenue momentum: chip product revenue grew 15 percent year over year to $88 million on DDR5 strength, management guided double-digit product growth for the next quarter, and the ramp of next-generation parts is what the valuation is leaning on.
Bull Case
The market is paying a steep multiple for Rambus, and the case for it is that the company sits at a chokepoint in the AI-memory build-out with a uniquely resilient business model. Rambus does two things at once: it sells the memory-interface chips that manage signal integrity on high-speed modules, and it collects royalties on the patents underlying memory interfaces. The 10-K frames the combination directly, pointing to "demand for our memory interface chips and stability from our royalties revenue," and the FY2025 numbers show the scale, revenue of $707.6 million with diluted net income of $2.11 a share. Product is the growth engine and royalties are the ballast, a mix few semiconductor names have.
The product growth is accelerating into exactly the demand the AI cycle is creating. First-quarter product revenue rose 15 percent year over year to $88 million, driven by DDR5 register clock drivers, the parts that let server memory run fast and reliably, and management guided double-digit product growth for the following quarter. Rambus is extending the franchise into the next memory generations, with offerings spanning an LPDDR5X server module chipset and an HBM4E memory controller, the high-bandwidth memory at the center of AI accelerators. Every new server and AI system needs more, faster memory, and Rambus's content per module rises as speeds climb.
The balance sheet turns that growth into pure optionality for the holder. Rambus carries about $786 million of net cash, covers interest more than 200 times over, and generated $83.2 million of operating cash flow in a single quarter. With essentially no debt and a flat share count, the company funds its IP and product roadmap entirely from cash flow and has the capacity to return capital or invest opportunistically without dilution. A business that earns royalties on the memory standard, sells the chips that implement it, and self-funds its expansion in cash is the kind of franchise the market pays up for when the underlying demand, AI memory bandwidth, is inflecting. The bull case is that the demand curve has a long way to run and Rambus's content rises with it.
Bear Case
The bear case is almost entirely about the price, and capital allocation makes the point sharper than the multiple alone. At roughly 60 times operating income, the price implies operating growth held at the company's self-funding ceiling for about twenty years. That is an extraordinary duration to underwrite, and history is unkind to it: only about 15 percent of comparable fast-growers sustained their pace for even ten years, let alone twenty. The recent rate is within what Rambus has delivered, so the assumption is not about the speed; it is about the persistence, and persistence at this length is where memory-cycle businesses have historically disappointed. The company keeps a fortress balance sheet and a flat share count rather than levering up or buying back stock aggressively, which is prudent, but it also means there is no financial-engineering lever to manufacture the per-share growth the price requires; it must all come from the operating business.
The cyclicality of memory is the structural threat the valuation ignores. Product revenue is tied to DDR5 module shipments, and memory demand moves in pronounced cycles of build-out and digestion; a single inventory correction in the server-memory supply chain would slow the product line that the multiple is extrapolating. The valuation methods register the disconnect across the board: no family reaches the price, with the earnings-power and asset-based methods landing at a small fraction of it and even the forward-growth methods below it. When every lens, including the one built to credit growth, says the price is rich, the stock is pricing a future beyond what any standard frame supports.
The royalty side adds its own quieter risk. Patent royalties depend on the patents staying valid and the licenses staying renewed; royalty revenue can step down as patents expire or as negotiations reset terms, and it does not compound the way product revenue can. Stripping out the cash, Rambus's demonstrated return on equity is in the mid-teens, solid but not the kind of number that justifies a 60-times operating multiple on its own. The bear does not need the company to stumble; it only needs the AI-memory demand to grow at a merely good pace rather than a spectacular one for two decades, and the price has left no room for the difference.
Valuation
What the price is betting is duration. At about 60 times company-wide operating income, today's price implies operating growth held at the self-funding ceiling for roughly twenty years. The near-term rate is consistent with what Rambus has recently delivered, so the demanding part is not the pace but the length of time it must persist, and only a small minority of fast-growers have sustained their growth for even half that horizon.
The methods are unusually unanimous. No valuation family reaches the price: the asset-based and earnings-power methods land at a small fraction of it, the relative-multiple methods well below it, and even the forward-growth methods, the ones designed to credit a high growth path, fall short. The earnings-power value, built on normalized operating income, sits far under the price because it refuses to assume the current peak earnings are permanent. That pattern, every lens calling the price rich, is the signature of a stock whose value rests on a future the standard methods cannot frame, which is to say an AI-memory growth runway extrapolated well beyond demonstrated economics.
Solvency is the one place the picture is unambiguously strong, and it reframes the bet as optionality rather than fragility. Rambus holds about $786 million of net cash, runs essentially no debt with interest covered more than 200 times, and generates strong operating cash flow with a flat share count. There is no balance-sheet risk and no financing dependence; the company funds its roadmap from cash. The price is therefore not underwriting survival, it is underwriting an exceptionally long stretch of high growth in the memory-interface franchise, with the cash position ensuring the company can pursue it but doing nothing to lower the bar the operating business must clear.
Catalysts
The first quarter showed the product line carrying the growth and the stock reacting to high expectations. Rambus reported GAAP revenue of $180.2 million, with product revenue of $88.0 million up 15 percent year over year on DDR5 register clock drivers, royalties of $69.6 million, and contract and other revenue of $22.6 million, alongside operating cash flow of $83.2 million. Management guided to double-digit product-revenue growth for the second quarter.
The roadmap catalysts are in next-generation memory. Rambus expanded its product and IP offerings for AI platforms, including an LPDDR5X server module chipset and an HBM4E memory controller IP, positioning it for the high-bandwidth memory used in AI accelerators. The signals to watch from here are the ramp of these newer parts, continued DDR5 share, and the stability of the royalty stream as patents and licenses roll. Because the stock had run hard into the print, the near-term tension is between strong absolute growth and the very high bar the valuation sets, so each quarter is judged less on whether growth is good and more on whether it is good enough to defend the multiple.
Peer Cohorts (Per Segment, With Filing Citations)
Rambus (consolidated) (reported)
- IDCC (INTERDIGITAL, INC.)
- FY2025 10-K: …referred to as the "consolidated financial statements"). We also have audited the Company's internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission…
- FY2025 10-K: …video and image compression to change the way that video is processed and ultimately distributed to connected devices and services. As part of the transaction, the vast majority of the acquired value was assigned to patents, with the remaining resulting in the recognition of goodwill. The goodwill is included in the…
- MTSI (MACOM Technology Solutions Holdings, Inc.)
- FY2025 10-K: August 6, 2019). 10.17* Offer of Promotion to John F. Kober, dated May 23, 2019 (incorporated by reference to Exhibit 10.2 to our Quarterly Report on Form 10-Q filed on August 6, 2019). 78 10.18* MACOM Technology Solutions Holdings, Inc. 2021 Omnibus Incentive Plan (incorporated by reference to Exhibit A to our Proxy…
- FY2025 10-K: …Statements of Operations 41 Consolidated Statements of Comprehensive ( L oss) Income 42 Consolidated Statements of Stockholders' Equity 43 Consolidated Statements of Cash Flows 44 Notes to Consolidated Financial Statements 45 37 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the stockholders and the Board…
- SMTC (SEMTECH CORP)
- FY2025 10-K: …Fiscal years 2025, 2024 and 2023 each consisted of 52 weeks. Certain reclassifications within the Consolidated Statements of Operations have been made to prior period amounts to conform to current period presentation, with no impact to the Company's gross profit, operating income, net income or earnings per share for…
- FY2025 10-K: , with a higher liability capped by the contractual maximum of the contingent earn-out obligation. Recent Accounting Pronouncements In November 2024, the FASB issued ASU 2024-04, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an…
- SLAB (SILICON LABORATORIES INC.)
- FY2025 10-K: …of segment assets is reported on the Consolidated Balance Sheets as Total assets. The CODM uses net loss to evaluate income generated in deciding whether to reinvest profits into the segment or to use such profits for other purposes, such as for acquisitions or share repurchases. Net loss is used to monitor budget…
- FY2025 10-K: …and is incorporated herein by reference. 43 Table of Contents Part IV Item 15. Exhibits and Financial Statement Schedules (a) 1. Financial Statements Index Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 34 ) F- 1 Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) F- 3…
- CRUS (Cirrus Logic, Inc.)
- FY2025 10-K: Association, as administrative agent. The Amendment updates the benchmark interest rate provisions to replace the London interbank offered rate ("LIBOR") with the forward-looking secured overnight financing rate ("Term SOFR"), for the purposes of calculating interest under the terms of the Second Amended Credit…
- FY2025 10-K: …loss. See Note 5 - Derivative Financial Instruments for additional information related to our hedging activities. 37 Table of Contents ITEM 8. Financial Statements and Supplementary Data Index to Consolidated Financial Statements Reports of Independent Registered Public Accounting Firm (PCAOB ID: 42 ) 39 Consolidated…
- MPWR (MONOLITHIC POWER SYSTEMS INC)
- FY2025 10-K: …the period ended December 31, 2025, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2025 and 2024, and the results of its…
- FY2025 10-K: The impacts of the restatement are summarized below (in thousands, except per-share amounts): RESTATED CONDENSED CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2025 (UNAUDITED) (in thousands, except par value): March 31, 2025 As Previously Reported Impact of Restatement As Restated ASSETS Current assets: Cash and cash…
- ALGM (ALLEGRO MICROSYSTEMS, INC.)
- FY2025 10-K: …Incentive Compensation Plan (Employees) (incorporated by reference from Exhibit 10.31 to the Company's Annual Report on Form 10-K filed on May 19, 2021) * 59 10.9 Form of Restricted Stock Unit Agreement under Allegro MicroSystems, Inc. 2020 Omnibus Incentive Compensation Plan (Executives) (incorporated by reference…
- FY2025 10-K: RT IV Item 15. Exhibit and Fi nancial Statement Schedules. The following documents are filed as part of this Annual Report: 1. Financial Statements. The following financial statements are included in this Annual Report from page F-1 to page F-45: Report of Independent Registered Public Accounting Firm (PCAOB ID Number…
- QRVO (Qorvo, Inc.)
- FY2025 10-K: …Supplies for such commodities may from time to time become restricted, or general market factors and conditions may affect the pricing of such commodities. We also have an active reclamation process to capture any unused gold. While we attempt to mitigate the risk of increases in commodity-related costs, there can be…
- FY2025 10-K: …which constituted a reporting unit within the HPA segment, and impairment testing was triggered. The impairment testing resulted in impairments of goodwill and intangible assets (primarily developed technology) of approximately $ 96.5 million and $ 16.6 million, respectively, recorded in "Goodwill and 63 Table of…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.
Sources
RMBS Q1 2026 results, April 27 2026 · RMBS Q1 2026 earnings call · RMBS Q1 2026 results